Australian drugmaker Clinuvel received orphan status for its treatment, Scenesse, which is an implant that is inserted under the skin.
The treatment is designed for adults with erythropoietic protoporphyria. For patients with the rare disorder, light exposure can be extremely painful and cause skin redness and thickening.
Side effects of the implant include implant site reactions, nausea, pain and fatigue.
Read the full news release here.
More articles on pharmacy:
Telemedicine startup to open first brick-and-mortar pharmacy
Top 10 pharmacy stories in September
Novant Health to open health clinics inside Walgreens
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.